FDA recalls delivery system of Sapien 3 Ultra within a week of approving it for low-risk patients

The FDA has issued a Class I recall—which it describes as “the most serious type of recall”—for the delivery system of the Sapien 3 Ultra transcatheter aortic valve implantation (TAVI) system. The recall follows Edwards Lifesciences receiving reports of burst balloons during implantation procedures, and it comes just under a week after the FDA [...]

FDA gives green light to four TAVI devices to be used for low-risk patients

The FDA has approved Evolut R, Evolut PRO (Medtronic), Sapien 3 and Sapien 3 (Edwards Lifesciences) for the management of low-risk patients with severe aortic stenosis. The approval follows the publication—in the New England Journal of Medicine—of two studies that showed positive results with these devices in low-risk patients. Prior to the FDA approval, [...]

2019-08-20T15:48:35+00:00August 20th, 2019|Tags: , , , , , , |

Edwards Lifesciences drops its self-expanding TAVI valve in favour of focusing on its balloon-expanding range

Source: BIBA MedTech TAVI Monitor Edwards Lifesciences—in a press statement announcing its global second quarter (Q2) financial results—has revealed that it is taking the self-expanding transcatheter aortic valve implantation (TAVI) device Centera off the market. The company says resources will instead be focused on the balloon-expanding Sapien range of TAVI devices, adding [...]

2019-08-09T11:01:06+00:00August 9th, 2019|Tags: , , , |
Go to Top